MANS peptide inhibits myristoylated alanine-rich C kinase substrate (MARCKS) by competing for membrane binding in cells, thereby inhibiting mucin secretion stimulation and tumor metastasis [1].

MANS peptide, at concentrations of 0-100 μM and incubation times of 12-24 hours, inhibits the migration and invasion of lung cancer cell lines CL1-0/F3, CL1-5, PC9, and A549 without causing toxicity to normal cells [1]. At a concentration range of 0-100 μM for 16 hours, MANS peptide suppresses the phosphorylation of MARCKS, PI3K, and AKT, leading to changes in downstream Slug signaling and E-cadherin expression levels. This results in the prevention of loss of cell-cell adhesion and alters the epithelial-mesenchymal transition (EMT) characteristics of cancer cells, thereby reducing tumor metastasis [1]. Cell Viability Assay [1] shows inhibited migration in the cell lines CL1-0/F3, CL1-5, and PC9 at the specified concentrations and incubation times. Western Blot Analysis [1] on cell lines CL1-0/F3, CL1-5, PC9, and NHBE indicates upregulated levels of E-cadherin and downregulated levels of Slug, with suppressed MARCKS phosphorylation and AKT/Slug pathway activity.

The MANS peptide, administered at a dosage of 50 nmol per injection via intraperitoneal injection every three days for a total of six doses, effectively inhibits tumor metastasis in a PC9 xenograft NOD/SCID mouse model without affecting tumorigenesis [1]. Animal Model: NOD/SCID mice model [1] Dosage: 50 nmol/injection Administration: Ip, every 3 days for 6 times Result: Suppressed micrometastatic lesions.